Coegin Pharma AB
Coegin Pharma AB, a biotechnology company, engages in developing peptide-based products for hair growth and skin pigmentation in Sweden. The company develops Follicopeptide, a peptide designed to enhance hair growth; and NPP-4, a natural pigmentation peptide 4 works by facilitating the transport of melanin to the skin, mimicking the natural process that occurs during sun exposure or tanning beds.… Read more
Coegin Pharma AB (7Z6) - Total Assets
Latest total assets as of September 2025: €13.89 Million EUR
Based on the latest financial reports, Coegin Pharma AB (7Z6) holds total assets worth €13.89 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Coegin Pharma AB - Total Assets Trend (2021–2024)
This chart illustrates how Coegin Pharma AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Coegin Pharma AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Coegin Pharma AB's total assets of €13.89 Million consist of 77.1% current assets and 22.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 72.8% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €6.05 Million | 22.4% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Coegin Pharma AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Coegin Pharma AB's current assets represent 77.1% of total assets in 2024, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 72.8% of total assets in 2024, down from 84.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 22.4% of total assets.
Coegin Pharma AB Competitors by Total Assets
Key competitors of Coegin Pharma AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Coegin Pharma AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Coegin Pharma AB generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Coegin Pharma AB is currently not profitable relative to its asset base.
Coegin Pharma AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.36 | 8.66 | 8.66 |
| Quick Ratio | 4.36 | 8.66 | 8.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €7.54 Million | € 9.00 Million | € 9.00 Million |
Coegin Pharma AB - Advanced Valuation Insights
This section examines the relationship between Coegin Pharma AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | 75.2% |
| Total Assets | €27.04 Million |
| Market Capitalization | $6.00 Million USD |
Valuation Analysis
Below Book Valuation: The market values Coegin Pharma AB's assets below their book value (0.22 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Coegin Pharma AB's assets grew by 75.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Coegin Pharma AB (2021–2024)
The table below shows the annual total assets of Coegin Pharma AB from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €27.04 Million | +75.20% |
| 2023-12-31 | €15.43 Million | -47.23% |
| 2022-12-31 | €29.25 Million | -3.59% |
| 2021-12-31 | €30.34 Million | -- |